Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:23
  • preuzimanja u poslednjih 30 dana:18

Sadržaj

članak: 2 od 46  
Back povratak na rezultate
2020, vol. 39, br. 4, str. 444-451
Rastvorljivi programirani smrtni ligand 1 (sPD-L1) i programirani smrtni ligand 1 (sPD-1) kao potencijalni biomarkeri za dijagnozu i prognozu kod pacijenata sa gliomom
aCapital Medical University, Beijing Tiantan Hospital, Laboratory Diagnosis Center, Beijing, China + Beijing Engineering Research Center of Immunological Reagents and Clinical Research, Beijing, China
bCapital Medical University, Beijing Tiantan Hospital, Laboratory Diagnosis Center, Beijing, China + Beijing Engineering Research Center of Immunological Reagents and Clinical Research, Beijing, China + Beihang University, Lab of Biological Science and Medical Engineering, Beijing, China

e-adresakangxxtt@sina.com
Projekat:
This work was supported by the National Science and Technology Major Project of China (2018ZX10307415-003).

Ključne reči: rastvorljivi programirani smrtni-1; rastvorljivi programirani smrtni ligand 1; gliom; biomarkeri; prognoza
Sažetak
Uvod: Ovo istraživanje imalo je za cilj da ispita mogućnost testiranja rastvorljivog programiranog smrtnog-1 (sPD-1) i rastvorljivog programiranog smrtnog liganda 1 (sPD-L1) u uzor cima seruma kod pacijenata sa gliomom i da proceni dijagnostičku i prognostičku vrednost ova dva rastvorljiva mole kula. Metode: Uzorci seruma uzeti od 70 pacijenata sa gliomom pre operacije označeni su kao preoperativna Pre-grupa, a uzorci dobijeni od 90 pacijenata sa glioblastomom posle operacije su označeni kao Post-grupa, dok su uzorci 20 zdravih dobrovoljaca korišćeni kao kontrolna grupa. Nivoi sPD-1 periferne krvi i sPD-L1 su detektovani korišćenjem ELISA kompleta i upoređeni su između grupa. Ispitivana je povezanost ovih nivoa rastvorljivih molekula sa kliničko-patološkim varijablama i napredovanjem tumora. Rezultati: Od tri grupe, Pre-grupa je imala najviši nivo sPD1, dok je srednji nivo sPD-L1 značajno niži u Post-grupi nego u ostale dve grupe. Područje ispod krive (AUC) sPD1 (0,762) za dijagnozu bilo je slično kao kod sPD-L1 (0,718). Viši serumski nivoi sPD-1 i sPD-L1 su bili prisutni u uzorcima pacijenata sa tumorom mozga u uznapredovalom stadijumu. Kaplan-Majerova analiza je pokazala da viši nivoi sPD-1 u serumu (>11,14 pg/mL) i sPD-L1 (>63,03 pg/mL) mogu ukazati na kraće vreme preživljavanja pacijenata sa gliomom bez progresije. Zaključak: Ova studija je pokazala da se sPD-1 i sPD-L1 mogu smatrati obećavajućim prediktivnim biomarkerima za dijagnozu i prognozu pacijenata sa gliomom.
Reference
Amatatsu, M., Arigami, T., Uenosono, Y., Yanagita, S., Uchikado, Y., Kijima, Y., Kurahara, H., Kita, Y., Mori, S., Sasaki, K., Omoto, I., Maemura, K., Ishigami, S., Natsugoe, S. (2018) Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer. Cancer Science, 109(3): 814-820
Berghoff, A.S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöhrer, A., Dieckmann, K., Filipits, M., Brandstetter, A., Weller, M., Kurscheid, S., Hegi, M.E., Zielinski, C.C., Marosi, C. (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology, 17(8): 1064-1075
Boussiotis, V.A., Chatterjee, P., Li, L. (2014) Biochemical signaling of PD-1 on T cells and its functional implications. Cancer Journal, 20(4): 265-271
Chang, B., Huang, T., Wei, H., Shen, L., Zhu, D., He, W., Chen, Q., Zhang, H., Li, Y., Huang, R., Li, W., Wu, P. (2019) The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy: CII, 68(3): 353-363
Chen, Y., Wang, Q., Shi, B., Xu, P., Hu, Z., Bai, L., Zhang, X. (2011) Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine, 56(2): 231-238
Dai, S., Jia, R., Zhang, X., Fang, Q., Huang, L. (2014) The PD-1/PD-Ls pathway and autoimmune diseases. Cellular Immunology, 290(1): 72-79
Garber, S.T., Hashimoto, Y., Weathers, S., Xiu, J., Gatalica, Z., Verhaak, R.G.W., Zhou, S., Fuller, G.N., Khasraw, M., de Groot, J., Reddy, S.K., Spetzler, D., Heimberger, A.B. (2016) Immune checkpoint blockade as a potential therapeutic target: Surveying CNS malignancies. Neuro-Oncology, 18(10): 1357-1366
Ha, H., Bang, J., Nam, A., Park, J., Jin, M.H., Bang, Y.H., Oh, D. (2019) Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during chemotherapy and its prognostic implications in cancer patients: Biomarker development in immuno-oncology. Cancer Research and Treatment, 51(2): 832-840
Liu, S., Wang, Z., Wang, Y., Fan, X., Zhang, C., Ma, W., Qiu, X., Jiang, T. (2018) PD-1 related transcriptome profile and clinical outcome in diffuse gliomas. OncoImmunology, 7(2): e1382792-e1382792
Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer, B.W., Kleihues, P. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica, 114(2): 97-109
Mahoney, K.M., Shukla, S.A., Patsoukis, N., Chaudhri, A., Browne, E.P., Arazi, A., Eisenhaure, T.M., Pendergraft, W.F., Hua, P., Pham, H.C., Bu, X., Zhu, B., Hacohen, N., Fritsch, E.F. (2019) A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunology, Immunotherapy: CII, 68(3): 421-432
Nduom, E.K., Wei, J., Yaghi, N.K., Huang, N., Kong, L., Gabrusiewicz, K., Ling, X., Zhou, S., Ivan, C., Chen, J.Q., Burks, J.K., Fuller, G.N., Calin, G.A., Conrad, C.A., Creasy, C., Ritthipichai, K. (2016) PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology, 18(2): 195-205
Nielsen, C., Ohm-Laursen, L., Barington, T., Husby, S., Lillevang, S.T. (2005) Alternative splice variants of the human PD-1 gene. Cellular Immunology, 235(2): 109-116
Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., Voloschin, A., Ramkissoon, S.H., Ligon, K.L., Latek, R., Zwirtes, R., Strauss, L., Paliwal, P., Harbison, C.T. (2018) Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology, 20(5): 674-686
Pratt, D., Dominah, G., Lobel, G., Obungu, A., Lynes, J., Sanchez, V., i dr. (2018) Programmed death ligand 1 is a negative prognostic marker in recurrent isocitrate dehydrogenase-wildtype glioblastoma. Neurosurgery
Reardon, D.A., Kim, T., Frenel, J., Santoro, A., Lopez, J., Subramaniam, D.S., Siu, L.L., Rodon, J., Tamura, K., Saraf, S., Morosky, A., Stein, K., Soria, J. (2016) ATIM-35: Results of the phase Ib KEYNOTE-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrent Pd-L1-positive glioblastoma multiforme (Gbm). Neuro-Oncology, 18(suppl_6): vi25-vi26
Reifenberger, G., Wirsching, H., Knobbe-Thomsen, C.B., Weller, M. (2017) Advances in the molecular genetics of gliomas: Implications for classification and therapy. Nature Reviews Clinical Oncology, 14(7): 434-452
Reiss, S.N., Yerram, P., Modelevsky, L., Grommes, C. (2017) Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas. Journal for ImmunoTherapy of Cancer, 5(1): 99-99
Ribas, A. (2015) Adaptive immune resistance: How cancer protects from immune attack. Cancer Discovery, 5(9): 915-919
Shigemori, T., Toiyama, Y., Okugawa, Y., Yamamoto, A., Yin, C., Narumi, A., Ichikawa, T., Ide, S., Shimura, T., Fujikawa, H., Yasuda, H., Hiro, J., Yoshiyama, S., Ohi, M., Araki, T. (2019) Soluble PD-L1 expression in circulation as a predictive marker for recurrence and prognosis in gastric cancer: Direct comparison of the clinical burden between tissue and serum PD-L1 expression. Annals of Surgical Oncology, 26(3): 876-883
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D.M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M.S., Fink, K., di Meco, F., Lieberman, F., Zhu, J., Stragliotto, G., Tran, D.D. (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA, 318(23): 2306-2316
Takada, K., Toyokawa, G., Shoji, F., Okamoto, T., Maehara, Y. (2018) The significance of the PD-L1 expression in non-small-cell lung cancer: Trenchant double swords as predictive and prognostic markers. Clinical Lung Cancer, 19(2): 120-129
van den Bent, M.J., Wefel, J.S., Schiff, D., Taphoorn, M.J., Jaeckle, K., Junck, L., i dr. (2011) Response assessment in neurooncology (a report of the RANO group): Assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol, 12(6): 583-93
Wang, Y., Jiang, T. (2013) Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management. Cancer Letters, 331(2): 139-146
Wang, Z., Zhang, C., Liu, X., Wang, Z., Sun, L., Li, G., Liang, J., Hu, H., Liu, Y., Zhang, W., Jiang, T. (2016) Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. OncoImmunology, 5(11): e1196310
Xu, J., Han, X., Liu, C., Gao, N., Zhao, J., Zhang, X., Jiang, L., Ren, L., Li, P., Wang, N. (2018) PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: A controlled study by pleural biopsy. Scientific Reports, 8(1): 11206-11206
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., Wu, K. (2018) Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Molecular Cancer, 17(1): 129-129
Zhou, J., Mahoney, K.M., Giobbie-Hurder, A., Zhao, F., Lee, S., Liao, X., Rodig, S., Li, J., Wu, X., Butterfield, L.H., Piesche, M., Manos, M.P., Eastman, L.M., Dranoff, G., Freeman, G.J. (2017) Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunology Research, 5(6): 480-492
Zhu, X., Lang, J. (2017) Soluble PD-1 and PD-L1: Predictive and prognostic significance in cancer. Oncotarget, 8(57): 97671-97682
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
PMC ID: PMC7710378
DOI: 10.5937/jomb0-24692
objavljen u SCIndeksu: 02.10.2020.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0

Povezani članci